Glp

• FDA kondigde nieuwe handhavingsmaatregelen aan gericht tegen compounding apotheken die GLP-1-geneesmiddelen zoals semaglutide produceren vanwege veiligheidsproblemen. • De aanpak richt zich op de risico's van niet-goedgekeurde versies van afslank- en diabetesmedicatie die de markt overspoelen. • Deze beleidswijziging is bedoeld om patiënten te beschermen tegen mogelijke contaminatie en doseringsfouten in de booming GLP-1-sector van 100 miljard dollar.

Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesityFaced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years. Continue reading...

• Major U.S. health insurers are limiting coverage of GLP-1 drugs like Ozempic and Wegovy to their original FDA-approved use for diabetes management, excluding weight loss treatments. • According to industry analyst Andy, this shift reverses prior expansions amid rising costs and supply shortages, affecting millions of patients seeking obesity care. • The policy change aims to control spending on these high-demand medications, which have seen off-label use surge, potentially pushing patients toward alternatives or out-of-pocket payments.